可溶性间皮素相关肽
快速浏览
为何检测？
监测一种少见肿瘤（间皮瘤）的进展或复发；这种肿瘤可影响包绕肺、心和腹腔的浆膜。大部分间皮瘤病例与患者暴露于石棉有关。
何时检测？
确诊间皮瘤后，在治疗期间或治疗后任何时候都可以进行该项试验从而追踪患者对治疗的反应。
何种样本？
采集自手臂静脉的血标本。
检测样本
检测什么？
这项试验检测血中一种被称为间皮素相关肽(SMRP)的小分子的含量。这些肽是包绕肺、心脏和腹部的脏层内膜上的蛋白的降解产物。间皮瘤患者的血液中常发现高水平的SMRP，而且血中 SMRP的含量被认为与病变程度有关。
恶性间皮细胞瘤是一种浆膜的少见肿瘤，这种浆膜包绕在内脏器官表面，是各种浆膜腔的脏层膜，包括胸腔(胸膜间皮瘤)、腹腔 (腹膜间皮瘤)以及心脏(心包间皮瘤)。在美国，每年有2,000到3,000 例新确诊的间皮瘤，其中胸膜间皮瘤是最常见的类型，占到所有病例的90%。大约70% 到 80%的胸膜间皮瘤患者有接触石棉的工作史，尤其是与造船、建筑、汽车业及防火工业有关。该疾病有较长的潜伏期，通常在接触石棉20到50年后才发展成间皮瘤。
测试样本如何采集？
通过针刺入静脉获取血液样本。
是否需要进行任何试验前准备以保证样本的质量？
不需要试验前准备。
试验
常见问题
询问检验医学专家
*请根据需要选择字段。
相关页面
站内
站外
National Cancer Institute: Fact sheet on Mesothelioma
Cancer Research UK: Mesothelioma
Explanation and Policies of Humanitarian Use Exemption from major cancer centers:
参考文献
注意：本文是在此处引用的参考文献和医学检验项目在线介绍编辑审核委员会全体成员的经验和研究结果的基础上总结而成。本文由编辑委员会定期审核、更新。任何新引用的文献都会添加到列表中，并且会与原有的参考文献区分开。
ARUP Laboratories. Soluble Mesothelin-Related Peptides (MESOMARK®). (March 2007, Issued). PDF available for download at http://www.aruplab.com/TestDirectory/resources/TechnicalBulletins/Soluble%20Mesothelin-Related%20Peptides%20(MESOMARK)%203-2007_Web.pdf through http://www.aruplab.com. Accessed on June 17, 2008.
U.S. Food and Drug Administration, Center for Devices and Radiological Health (February 22, 2007, Updated). New Humanitarian Device Approval: Mesomark ™ - H060004. Available online at http://www.fda.gov/cdrh/mda/docs/H060004.html. Accessed on June 16, 2008.
Email interview with David Grenache, Medical Director, Special Chemistry, ARUP Laboratories, Salt Lake City, Utah. June 20, 2008.
Pacific Heart & Blood Institute. Mesomark. Available online at http://www.phlbi.org/mesomark_available.asp. Accessed June 17, 2008.
ARUP Laboratories. The Physician’s Guide to Laboratory Test Selection and Interpretation: Mesothelioma. Available online at http://www.arupconsult.com/Topics/OncologicDz/Mesothelioma.html through http://www.arupconsult.com. Accessed June 17, 2008.
Fujirebio Diagnostics. FAQ: The Mesomark Assay. Available at http://www.fdi.com/mesomark/world/about/faqs.html#4 through http://www.fdi.com. Accessed June 18, 2008.
Beyer, H. et al. Mesomark ™: A Potential Test for Malignant Pleural Mesothelioma. Clinical Chemistry 2007: 53: 666-672.
Creaney, J. et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62: 569-576.
U.S. Food and Drug Administration. Center for Devices and Radiological Health Guidance for Industry and FDA Staff: Humanitarian Device Exemption (HDE) Regulation: Questions and Answers. (July 18, 2006, Issued). PDF available for download at http://www.fda.gov/cdrh/ode/guidance/1381.pdf through http://www.fda.gov. Accessed June 16, 2008.
Fujirebio Diagnostics. Healthcare Professionals: Mesomark ® Approved for Humanitarian Use in the U.S. Available online at http://www.fdi.com/mesomark/usa/professionals/healthcare_professionals.html through http://www.fdi.com. Accessed June 18, 2008.
Cancer Research UK. Mesothelioma Risks and Causes. (February 5, 2008, Updated). Available online at http://www.cancerhelp.org.uk/help/default.asp?page=4395 through http://www.cancerhelp.org.uk. Accessed June 20, 2008.
National Cancer Institute. Mesothelioma: Questions and Answers. (May 13, 2002, Reviewed). Available online at http://www.cancer.gov/cancertopics/factsheet/Sites-Types/mesothelioma through http://www.cancer.gov. Accessed June 20, 2008.
